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Abstract
Purpose of Review The consequence of treatment for gynaecological cancers can cause sudden onset of intense men-
opausal symptoms, such as vasomotor symptoms, sexual dysfunction and emotional instability. Hormone replacement
therapy (HRT) is often effective and can overcome these unpleasant and severe symptoms. However, data regarding its
safety remains controversial. The big question therefore is whether HRT in gynaecological cancer survivors is possible.
This is due to the fear of disease relapse. So, the purpose of this study was to review the evidence regarding cancer
recurrence or death following use of HRT in survivors of gynaecological cancers.
Recent Findings For endometroid endometrial cancer, most of the retrospective studies concluded that there was no
increase in recurrence rate of endometrial cancers in HRT versus non-HRT users. HRT should be particularly avoided in
epithelial ovarian tumours particularly serous cancers and serous borderline tumours due to expression of oestrogen
receptors. Given the lack of evidence on the impact of HRT on recurrence and disease-free survival in survivors of cervical
cancers, it would seem perfectly reasonable to prescribe HRT, particularly if they are premenopausal. Many clinical
guidelines would consider the use of HRT to be contraindicated in breast cancer survivors based on limited RCT evidence.
Summary Current scientific data, comprising mainly of retrospective studies, suggest that recurrence rates and survival are
comparable between HRT users and non-users. Women should know the paucity of safety data regarding the use of HRT.
Wherever possible, non-hormonal alternatives to HRT should be considered in all women. If non-hormonal alternatives fail to
achieve adequate control of symptoms, then it is possible to consider the HRT after careful counselling of the patient as well as
involvement of the oncology team in the decision-making process. However, more robust randomised controlled trials are needed
to get convincing data regarding the safety of HRT in gynaecological cancer survivors.
Keywords Hormone replacement therapy (HRT) . Gynaecological cancers . HRT alternatives . Menopause .
Vulvovaginal atrophy (VVA) . Cancer survivors
Introduction
One of the consequences of treating gynaecological and
breast cancer in younger women is abrupt loss of ovarian
function. As a result of iatrogenic menopause, these wom-
en often have to deal with intense and sudden onset of
menopausal symptoms such as vasomotor symptoms,
genito-urinary dysfunction, sleep and mood disturbances.
These symptoms are often exacerbated by the cancer treat-
ment [1]. Expansion of screening programmes, increasing
patient awareness, early diagnosis, and progress in the
treatment of gynaecological cancer has led to prolonged
survival of women living with gynaecological cancers.
As a result, there is a demand for greater attention towards
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improving quality of life and minimising long-term conse-
quences of oestrogen deficiency in these women. It is often
difficult to provide appropriate advice regarding hormonal
replacement therapy (HRT) in women after gynaecological
cancer treatment due to paucity of evidence and published
guidance. In addition, the safety of HRT in this group of
women is controversial due to the possible hormone-
dependent nature of some of the cancers and hence opinion
is divided.
Conventional HRT is highly effective in alleviating meno-
pausal symptoms, improving quality of life and in reducing
the long-term risk of osteoporosis and cardiovascular disease
[2, 3]. The major concern about HRT use in gynaecological
and breast cancer survivors is the fear of recurrence. This
article reviews the available evidence specific to the risk of
HRT in women who are survivors of gynaecological and
breast cancer and also provides evidence-based recommenda-
tions regarding the use of HRT and its alternatives. This re-
view is based on the available literature which consists mainly
of retrospective, observational and case-control studies.
HRT and Endometrial Cancer (EC)
Uterine cancer is the most common gynaecological cancer in
the UK second only to breast cancer with 8984 cases diag-
nosed in 2015 [4]. The incidence of this is increasing second-
ary to the obesity epidemic. Althoughmost commonly seen in
postmenopausal women, 30% of cases are seen in premeno-
pausal women [5, 6]. The standard treatment is hysterectomy
and bilateral salpingo-oopherectomy (with or without chemo-
radiotherapy), and as such these women may suffer from sud-
den iatrogenic morbidity associated with menopause.
The commonest histological subtype is endometrioid endo-
metrial cancer and its association with unopposed oestrogen
exposure is well established [6, 7]. Several studies have re-
ported higher risks of endometrial cancer in HRT users than in
non-users, but this was confined to particular sequential regi-
mens; conjugated equine oestrogen and medroxy progester-
one acetate, which is rarely used in the UK. Moreover, the
incidence has been shown to be decreased in users of contin-
uous combined HRT [8, 9]. As a result, advice on HRT use,
particularly in early-stage endometrial cancer is uncertain.
Most of the studies published in the literature are in youn-
ger women, particularly with a history of type 1 endometrial
carcinoma and early stages of the disease. There have been a
few retrospective studies which concluded that there was no
increase in recurrence rate of endometrial cancers in HRT
versus non-HRT users [10–13, and). In a prospective trial with
49.1months follow-up, Ayhan et al. 2006 found no increase in
recurrence rate of endometrial cancer after the use of HRT
[14]. However, the number of subjects in this study was low
(50 HRT users vs 61 NON users). The only prospective
randomised control led tr ial (RCT) was from the
Gynecologic Oncology Group (GOG) [15]. It randomised
1236 women with stages 1–2 adenocarcinoma to oestrogens
alone or to placebo group for 3 years. As a result of the pub-
lication of the WHI study [16], this study was closed prema-
turely after a mean follow-up of 35 months. No significant
difference was observed in the recurrence rate, which was
extremely low in both groups (2.1% in the 618 HRT users
versus 1.9% in the placebo groups).
No other study has so far reported a detrimental effect of
HRT in early-stage endometrial cancer survivors. However,
these studies vary in study design, timing of HRT after sur-
gery, uniformity with regard to doses, duration of administra-
tion and addition of progestin. Only one study was
randomised, therefore patients who wish to start HRT may
be those who will benefit less from treatment. Although the
results do not completely exclude the possibility of HRT in-
creasing the risk of recurrence, they suggest that the magni-
tude of such a risk is not large.
Serous papillary and clear cell carcinomas are both aggres-
sive variants of EC with a poor prognosis, even when diag-
nosed at an early stage. They account for approximately 8% of
all EC and occur mainly in postmenopausal women. They
lack oestrogen and progesterone receptors and thus are not
considered to be stimulated when HRT is used after surgical
treatment. Uterine sarcomas are a heterogeneous group of EC
including carcinosarcomas, leiomyosarcomas, adenosarcomas
and endometrial stromal sarcomas. Only the latter type is con-
sidered oestrogen-dependent as it expresses oestrogen and
progesterone receptors and HRT should be avoided in them
[17]. However, there are no studies published regarding the
safety of HRT in these histological subtypes and the impact of
HRT is unknown. Also, most occur in postmenopausal
women.
HRT and Ovarian Cancers
Ovarian cancer is the next most common gynaecological can-
cer after uterine cancer with 7270 cases diagnosed in 2015 [4].
Over 90% of ovarian cancers are of epithelial origin and it is
the leading cause of death amongst gynaecological malignan-
cies in many areas of the world [18, 19]. At diagnosis, more
than 75% of women have advanced stage disease and their 5-
year survival is poor, not exceeding 45%. For this reason,
focus upon quality of life after treatment may become increas-
ingly important for some women and relief of menopausal
symptoms may, for some, outweigh the fear of recurrence
[18].
In preclinical studies, the pathogenesis seems to be at least
partly hormonally influenced [20] and a number of in vitro
experiments have indicated that oestrogen is capable of pro-
moting the growth of ovarian cancer cells [21]. Also, a meta-
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analysis of 21,488 post-menopausal women who used HRT
for over 5 years showed an increased risk of ovarian cancer
(Collaborative Group On Epidemiological Studies Of Ovarian
Cancer, 2015) although numerically, the absolute increase in
risk was small (1/1000 users) [22]. Antiestrogens and aroma-
tase inhibitors such as tamoxifen and letrozole have now been
used in relapsed cases of ovarian cancers and who do not
tolerate first-line chemotherapy. This is with the understand-
ing that certain epithelial ovarian tumours express oestrogen
and progesterone receptors [23–25, and).
However, there are no clear data demonstrating adverse
outcomes in ovarian cancer patients taking HRT. A few ob-
servational studies and RCT have demonstrated favourable
outcome in ovarian cancer survivors using HRT for over
24 months versus non-users [20, 26–30). For women with
borderline tumours, observational studies using HRT has
shown a better 5-year survival rate as compared to invasive
tumours [27].
Low-grade serous carcinomas are almost always diffusely
positive with oestrogen receptor and HRT is normally avoided
in this subtype of ovarian cancer [23]. 10% of epithelial ovar-
ian cancers are borderline tumours [31]. These are heteroge-
neous tumours and treatment is always individualised. Expert
opinion is that these are tumours with potential to turn into
low-grade serous cancers and hence better to avoid HRT in
serous borderline tumours depending on the severity of the
symptoms. There are no studies for use of HRT after clear cell
and endometrioid ovarian cancers. However, due to the
hormone-dependent nature of some of these tumours, some
believe that there is a theoretical risk of disease reactivation
with the use of unopposed or cyclical HRT.
Ovarian germ cell and sex cord stromal tumours are often
seen in young premenopausal women and thought to be hor-
mone-dependent. No studies examining the use of HRT in
these subsets are available.Whilst it can be considered in early
stage and unilateral tumours, HRT should be avoided and
alternatives discussed [18].
HRT and Cervical Cancer
Pre-invasive and early invasive cervical cancers are often
treated with conservative surgery in young women, therefore,
HRT is usually considered in advanced stages. HRT has never
been linked to development of squamous cell carcinoma of the
cervix which amounts to 80% of the cases. There is, however,
epidemiological data linking the oral contraceptive pill to ad-
enocarcinoma of the cervix with a relative risk of 2.2 after 10-
year use [32]. There is no data on HRT use in these women.
Ploch et al. reported no impact on 5-year survival with HRT
use in stage 1 & 2 cervical cancers and noted fewer radiother-
apy complication rates in these women [33]. Given the lack of
evidence on the impact of HRTon recurrence and disease-free
survival, it would seem perfectly reasonable to prescribe HRT
for survivors of cervical cancers, particularly as they are likely
to be premenopausal.
HRT and Vulvo-Vaginal Cancers
These cancers account for a very small number of cases, main-
ly affecting postmenopausal women. Apart from some con-
troversy about melanoma due to unconfirmed reports that it is
hormone-dependent, cancers of the vulva and vagina are not
hormone-dependent and it is believed that there is no contra-
indication to the use of HRT in women treated for vulva or
vaginal neoplasm [34].
HRT and Breast Cancers
In 2015, there were 55,122 new cases of invasive breast can-
cer diagnosed across the UK which accounts for almost one
third of all diagnosed cancers in women [4]. In UK, over the
last decade, breast cancer mortality rates have decreased by
more than a fifth (22%) secondary to early diagnosis and ad-
vancements in treatment. As a consequence of primary
chemo-radiation and adjunctive endocrine therapy, many
breast cancer survivors suffer from severe and sudden onset
of climacteric symptoms and reduced quality of life.
Oestrogen receptor (ER) and progesterone receptor (PR) pos-
itivity is found in 75% of breast cancers [35]. In these women,
the most effective treatment for menopausal symptoms would
be HRT, however, its use in breast cancer survivors is varied
and controversial based on the fact that prevention of recur-
rence of hormone receptor-positive tumours involves using
adjuvant anti-oestrogen therapy such as tamoxifen and/or aro-
matase inhibitors that decrease the circulating level of
oestradiol to almost zero [36, 37••].
Col et al. reported meta-analyses of eight studies in Stage
1–4 breast cancer survivors who used oestrogen only or
oestrogen + progesterone HRT. These showed reduced breast
cancer recurrence over a 5-year follow-up period in women
using HRT [38]. However, this was found to be confounded
by selection bias. Several other observational studies sug-
gested that HRT after breast cancer has no adverse impact on
recurrence and mortality [39–42].
Many clinical guidelines would consider the use of HRT to
be contraindicated in breast cancer survivors based on limited
RCT evidence [37••, 43, 44••, 45]. The two main RCTS are
the HABITS (hormonal replacement therapy after breast
cancer—is it safe?) and Stockholm trial [46–48]. Both trials
compared oestrogen with or without a progestogen against a
placebo. Although there was no difference in recurrence rates
in HRT users, the Stockholm trial (Hazard Ratio -HR 0.82)
was prematurely stopped due to high recurrences in the
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HABITS trial (HR2.2). The adverse outcome in HABITS has
been imputed to higher progestogen exposure and less con-
comitant tamoxifen use compared with the Stockholm trial.
Another RCT using tibolone also found an increased risk of
recurrence in breast cancer survivors (HR 1.40) [49]. Due to
the above data, HRT is usually contraindicated after breast
cancer diagnosis. However, if alternatives to HRT fail to
achieve adequate control of symptoms, then it is possible to
consider the HRT after careful counselling of the patient as
well as involvement of the oncologist and breast team in the
decision-making process.
HRT in BRCA 1 & BRCA 2 Gene Carriers
The National Comprehensive Cancer Network (NCCN) rec-
ommends risk reducing bilateral salpingo-oophorectomy
(RRBSO) for women with BRCA1 mutations between ages
35 and 40 and for BRCA2mutations between 40 and 45 years
in order to prevent ovarian and fallopian tube cancers [50].
Thus, RRBSO significantly decreases overall mortality and
risk of tubo-ovarian cancers in BRCA positive women with
or without history of breast cancer as well as lowers the risk of
first diagnosis of breast cancer in BRCA mutation carriers
[51–54].The consequence of RRBSO is iatrogenic early men-
opause. If these women do use HRT, it results in overall de-
creased mortality [55, 56]. However, the controversy here is
the potential augmentation of already elevated breast cancer
risk with the use of HRT in BRCA gene carriers.
The Women’s Health Initiative (WHI) trial was stopped
prematurely after demonstrating an increased risk of breast
cancer in the oestrogen plus progesterone arm (HR 1.26) as
compared to placebo after 5.2 years follow-up. Given that
WHI participants had an average age of 63 years at enrolment,
it is unclear how these data apply to women with premature
surgical menopause. The other interesting fact from the WHI
trial was that this increased risk in breast cancer was seen with
the use of oestrogen plus progesterone HRT (E+P) (HR 1.26),
but not with oestrogen-only HRT (HR 0.77) [3].
Since then, both prospective and retrospective studies have
been published, demonstrating that the use of HRT is not
associated with increased risk of breast cancer after RRBSO
in BRCA carriers [57–59, 60••]. In the prospective, cohort
study of premenopausal BRCA carriers (PROSE), RRBSO
was significantly associated with reduction of breast cancer
risk (HR = 0.40) without alteration of this risk with the use of
HRT of any type (HR0.37). In this study, women predomi-
nantly took oestrogen alone HRT rather than oestrogen plus
progesterone [57]. In 2016, Kotsopoulos et al. reported no
adverse effect of oestrogen-alone or of combined oestrogen
plus progesterone (E+P) formulations on breast cancer risk in
BRCA1 mutation carriers after RRBSO [59]. A subset analy-
sis of this study showed oestrogen-containing HRT was
associated with an 18% reduction in breast cancer risk (HR
0.82, 95% CI 0.69–0.97, p = 0.02) while each year of
progestin-containing HRT (progestin-alone or E + P) was as-
sociated with a non-significant (14%) increase in breast cancer
risk (HR 1.14, 95% CI 0.90–1.46, p = 0.28) [60••].
Finally, there has been some consideration of interval
salpingectomy with delayed oophorectomy (ISDO) for risk
reduction which can reduce the adverse effects of early men-
opause by delaying its onset. Currently, there is insufficient
data to recommend it over RRBSO in BRCA 1 & BRCA2
carriers. The fear of breast cancer risk by patients and pro-
viders is often the major deterrent from starting HRT.
However, based on the available literature, breast cancer risk
reduction following RRBSO in premenopausal BRCA car-
riers without a history of breast cancer is not changed due to
HRT. Hence, with the current available data, it would be safe
and beneficial to use HRT in these women.
Management Strategies
The key principles for management are to determine the age of
the women, type and prognosis of the cancer, severity of the
signs and symptoms related to oestrogen deficiency and the
extent to which this impacts the quality of life. This allows
treatment to be individually tailored based on these assess-
ments. For mild symptoms, maintenance of health, lifestyle
modifications or over the counter options may be sufficient.
Moderate or severe signs or symptoms usually require phar-
macological management. Routine testing for hormone status
in tumours should now be considered and this will help to
determine the hormone-dependent nature of the
gynaecological tumour and guide discussions regarding the
use/consideration of HRT.
The absolute risks of each potential complication of HRT
must be interpreted once an individual’s background risk has
been considered. Although HRTmay increase the relative risk
of a complication occurring, the overall absolute risk may
remain low and this risk must be carefully presented to the
individual. Multidisciplinary planning can often help with de-
cision making regarding best management option for meno-
pausal symptoms. Discussing systemic HRT in breast cancer
sufferers is outside the scope of this review since it is an
absolute contraindication. Below are some of the alternatives
to systemic HRT that can be considered in women in whom
HRT is contraindicated or for those who wish to avoid it.
Lifestyle Modifications
There is some evidence that healthy lifestyle behaviours can
improve some symptoms of the menopause—particularly va-
somotor symptoms, such as hot flashes and night sweats.
There is also some evidence that women who are more active
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tend to have fewer symptoms of the menopause [61].
Furthermore, a calorie-controlled diet, with an aim to lose
10% or more of the body weight, may modify the incidence
of VMS [62]. Diet rich in calcium (1000 mg/day) and Vitamin
D (10 mcg/day) will help prevent development of osteoporo-
sis and hence risk of fractures. Stopping smoking and cutting
down on alcohol may also reduce the frequency of hot flashes
as well as the risk of heart disease and osteoporosis long term
[63].
Alternatives to HRT
Most alternative therapies are evaluated in respect to vasomotor
symptoms, and somemay also have an effect onmood (Table 1).
The placebo effect has been reported to be as great as 30–50% in
many studies in addition to its baseline effect and for some, that
in itself might be considered a treatment option [64].
Alternative Techniques Acupuncture, yoga, reflexology,
homoeopathy and hypnosis have been described to be useful
in managing menopausal symptoms but no strong data exists
to support this [65, 66]. As with the therapies mentioned
above, whilst many women may find some of these tech-
niques helpful, more research is required to fully understand
their mechanism of action and effectiveness. However, when
used properly with advice from qualified professionals, it is
unlikely that any harm will be caused. NICE (2015) recom-
mends Cognitive Behavioural Therapy (CBT) as a treatment
option for anxiety experienced by women during the meno-
pause transition and post-menopause [67]. CBT, developed
specifically for menopausal symptoms, can help women with
vasomotor symptoms and has been found to be effective in
three clinical trials for women going through the menopause
and for breast cancer patients [68–70].
Management of Vulvo-Vaginal Atrophy (VVA)
The genito-urinary tract is where the most significant localised
menopausal side effects are seen. Loss of oestrogen results in a
decrease in the number of parabasal cells, an increase in vag-
inal pH, as well as increased dryness and susceptibility to
infections. Oestrogen deficiency also results in atrophy of
the bladder and urethral epithelium making it susceptible to
infections and symptoms of urinary frequency and urgency,
nocturia, dysuria and incontinence are noted [71, 72].
Systemic hormone replacement therapy (HRT) can alleviate
vaginal symptoms. The rise in serum oestradiol levels stimu-
lates revascularisation and regeneration of the collagen of vag-
inal and lower urinary tract epithelium. However, the British
Menopause Society and National Institute of Health and
Table 1 Alternatives to HRT
Class and drug Adverse effect Dose Precaution
a) Prescribable
SNRI–Antidepressant Dizziness, sexual dysfunction Venlafaxine 37.5 mg daily to
max 150 mg/day
No interaction with
cytochrome P450 so it may
be the safest choice for
patients on anticancer drugs
SSRI–antidepressants Nausea, dizziness, sexual
dysfunction, short term
aggravation of
anxiety/depression
Paroxitine 10–20 mg Drug interaction: Interacts
with enzyme cytochrome
P450 (CYN10)
Citalopram 20 mg
Sertraline 25–50 mg
Fluoxitine 20 mg
Central anti-hypertensive Sleep disturbance, dry mouth,
nausea and fatigue
Clonidine 25–150 mcg/day Slow titration of doses needed.
Interaction with other
anti-hypertensives
(licenced option)
Antiepileptic/analgesic Dry mouth dizziness,
drowsiness and weight gain
(Gabapentin ≫ Pregabalin)
Gabapentin
300–900 mg/daily
Weight gain
Pregabalin 50–300 mg/day
b) Over the counter medications
Phytoestrogens No more than Normal levels
of dietary Intake
Poor quality evidence and
inconsistent data
Herbal remedies-Black
Cohosha, St Johns wart,
Evening Primrose
Constipation, arrhythmia,
weight gain, abdominal
cramps
No recommendation on
dosing
Many contain steroid
hormones (including
oestrogen). Not tested for
safety and efficacy. Drug
interactions
a Black cohosh is contraindicated in patients who have active liver disease or a history of liver damage. Liver toxicity has been associated with
contaminants in black cohosh. But there is no causality data to back up this suggestion. It is available over the counter in Europe
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Clinical Excellence (NICE) recommend that when the symp-
toms are predominantly vaginal or urogenital, topical treat-
ment should be used [71].
The following table summarises different options for
VVA. Usually, non-hormonal options are the first line of
treatment in women with breast and hormone-dependent
gynaecological cancers (Tables 1 and 2). There have been
no concerns with the safety and their use in these women.
High-sensitivity assays have demonstrated that all vaginal
oestrogen preparations result in a minor degree of systemic
absorption but not exceeding normal postmenopausal
levels [45]. Data regarding the safety of vaginal oestrogen
therapy in breast cancer survivors are limited. Low-dose
vaginal oestrogen in women taking the anti-oestrogens like
tamoxifen might be theoretically safer than in women not
receiving these agents because of blockade of some possi-
ble effects of systemic oestrogen absorption [73]. Some
observational and case-controlled data show reassuring re-
sults with the use of vaginal oestrogen concurrently with
tamoxifen [41, 73, 74]. However, the same is not available
for aromatase inhibitors. Therefore, in general, the use of
vaginal oestrogen is discouraged in women using aroma-
tase inhibitors in breast cancer survivors [37••, 44••].
Detailed counselling of the patient, as well as liaison with
the oncology team, is essential before considering local
hormonal therapy in these women and, if used, should be
at the lowest dose possible.
In 2014, a meta-analysis concluded that there is no in-
creased risk of recurrence in women who are taking systemic
HRT following treatment of endometrial cancer [75].
Although there have been some concerns regarding the use
of systemic treatment following ovarian cancer, there are no
data to suggest an increased risk of recurrence with either
systemic or local oestrogen therapy [17].
Ospemiphene, an oral SERM, has been approved in
Europe and North America for the treatment of dyspareunia
secondary to VVA in healthy postmenopausal women.
However, current FDA labelling in the USA recommends
against the use of ospemiphene in women with a history of
breast cancer, until results from an adequately powered RCT
of its effect on the breast are available. Similar safety concerns
exist with the use of tissue-selective oestrogen complex,
phytoestrogens and testosterone/DHEA vaginal gels due to
their potential estrogenic activity in women with breast and
other gynaecological cancers.
What’s on the Horizon?
Recent data suggest that neurokinin B in the arcuate nucleus
mediates menopausal hot flashes. On this basis, two
randomised placebo-controlled trials have evaluated the ef-
fects of oral neurokinin B receptor antagonists on hot flashes.
Both agents (MLE 4901 and fezolinetant) reduced hot flash
Table 2 Management option for
VVA Class and drug Route/dose Precaution
A) Non-hormonal
Vaginal moisturisers
and lubricants-SYLK,
Replens MD, Yes,
Vagisil
Vaginal lubricants
just before sexual
intercourse.
Moisturisers twice
weekly
Cost
Short-term relief
Useful in mild-moderate VVA
Laser (Erbium and CO2) Vaginal Cost, limited data on safety and efficacy
B) Hormonal
Vaginal oestrogen:
Vagifem, Ovestin,
Orthogynest, Gynest,
Estring
Vaginal
Daily × 2 weeks.
Twice weekly
Lack of safety data, caution in
women who have contraindications
to oestrogen
Selective ER modulator Ospemiphene
60 mg/daily
Tissue-selective
oestrogen complex
treatment
Oral (conjugated
oestrogen
0.45 mg +
Benzadoxifene 20 mg)
Phytoestrogen:
isoflavone
gel
Vaginal Gel
Androgens and
DHEA
Vaginal DHEA
6.5 mg/night
Testosterone gel
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frequency and severity by 40% to 50% over placebo in post-
menopausal women, with negligible side effects [76, 77]. As
these inhibitors act on specific hot-flash mediating pathways,
they show promise as effective, non-hormonal agents to treat
hot flashes particularly useful in survivors of hormone-
dependent gynaecological cancers. Long-term safety data for
these drugs are still awaited. This drug is currently used only
in trial setting testing for effectiveness and appropriate dosing
schedule.
Conclusion
Treatment for gynaecological cancer in young women can
cause sudden onset of intense menopausal symptoms,
mainly vasomotor symptoms and sexual dysfunction.
Hormone replacement therapy (HRT) has often proved
to be very effective in the treatment of these unpleasant
and often severe menopausal symptoms. However, its
safety remains controversial. We have reviewed English
language literature and examined whether administration
of HRT in this specific population is associated with more
recurrences and worse prognosis. Current scientific data,
comprising mainly of retrospective studies, suggest that
recurrence rates and survival are comparable between
HRT users and non-users. However, large randomised tri-
als are missing and definitive conclusions cannot be
drawn. Gynaecological cancer survivors using HRT
should be informed about the lack of strong evidence
regarding the risk of recurrence with the use of HRT.
Positive effect of HRT on quality of life in these women
cannot be disregarded. In this regard, additional well-
designed RCTs considering all potential confounding fac-
tors, including cancer characteristics and treatment, differ-
ent types of HRT, the disease-free-interval before HRT
initiation and the duration of HRT use are needed to ob-
tain conclusive recommendations.
In the meantime, what should we do? It is important that
the available literature is interpreted with caution and present-
ed to each woman enabling every patient to make informed
decision with the support of the multidisciplinary specialist
team regarding the use of HRT. If HRT is not desired or con-
sidered contraindicated, nonhormonal alternatives can be of-
fered safely in the vast majority.
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